Recruiting

Observational Study

Sponsor:

Universal Diagnostics

Code:

NCT04792684

Conditions

Colorectal Cancer (CRC)

Advanced Adenomas (AA)

Eligibility Criteria

Sex: All

Age: 45 - 70+

Healthy Volunteers: Accepted

Interventions

Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel

Study Details

Brief summary:

A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.

Conditions

Colorectal Cancer (CRC)

Advanced Adenomas (AA)

Study ID

NCT04792684

Start date

Dec 30, 2020

Status verified date

Nov, 2025

Completion date

Dec 30, 2025

Anticipated

Primary completion date

Dec 30, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 45 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

Arm A:

1. Must be 45-84 years of age.
2. Must have a suspected advanced adenoma or be newly diagnosed with CRC, still not resected, and scheduled for surgery.
3. Able to comprehend, sign, and date the written informed consent document.

Arm B:

1. Must be 45-84 years of age.
2. Able and willing to undergo a standard-of-care screening colonoscopy within 60 days.
3. Able to comprehend, sign, and date the written informed consent document.

Exclusion Criteria:

Arm A Only:

1\. Subject with curative biopsy during colonoscopy.

Arm B Only:

1. Subjects with positive FIT Test results in the 6 months preceding enrollment.
2. Subject has a current diagnosis of cancer.

Arms A \& B:

1. Subject has a personal history of aerodigestive or digestive tract cancers.
2. Subjects having undergone previous partial surgical removal of one or more portions of their colon due to a reason other than colorectal cancer.
3. Has a known diagnosis or personal history of any of the following high-risk indications for colorectal cancer:

1. Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
2. Familial adenomatous polyposis ("FAP", including attenuated FAP).
3. Hereditary non-polyposis colorectal cancer syndrome ("HNPCC" or "Lynch Syndrome").
4. Serrated polyposis syndrome
5. 2 first-degree relatives (e.g., parents, siblings, and offspring) who have been diagnosed with colon cancer.
6. One first-degree relative with CRC diagnosed before the age of 60.
4. A significant disease which, in the Investigator's opinion, would exclude the subject from the study.
5. Legal incapacity or limited mental capacity.
6. Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent.
7. The patient has a known or documented previous or current medical history of infectious diseases that can be transmitted through blood (E.g. Hepatitis, HIV, etc.), including patients that have been treated, are currently being treated, or have not been treated for that conditions.
8. The patient is known to be pregnant when recruited or during her participation in the study.

Study Design

Enrollment

1300 participants

Anticipated

Interventions and Outcome Measures

Arms

Arm A.

Subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC still not resected and scheduled for surgery

Arm B

Subjects at average-risk for CRC and scheduled for CRC screening colonoscopy

Interventions

Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel

Evaluate the performance of a preliminary panel of biomarkers

Primary outcome measure

  • Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing [ Time Frame: Within 12 months of sample collection ]

Central Contacts and Locations

Central contacts

Locations

Lakeland Regional Cancer Center

Recruiting

Lakeland, Florida, United States, 33805

Springfield Clinic

Recruiting

Springfield, Illinois, United States, 62702

Mid Hudson Medical Research

Recruiting

New Windsor, New York, United States, 12553

University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

More Information

Sponsor

Universal Diagnostics

Last update posted

Nov 10, 2025

Last verified

Nov, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Universal Diagnostics on 2025-11-10.